Upstate Active Clinical Trials
Study Title:Alliance A031203: Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
What is the purpose of the study?This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated locally advanced or metastatic kidney cancer. Cabozantinib-s-malate and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cabozantinib-s-malate or sunitinib malate is more effective in treating patients with kidney cancer.
Upstate Institutional Review Board (IRB) Number:554082
Patient Age Group:Adults
Principal Investigator:Sam Benjamin, MD
Who can I contact for more information?
Name: Wendy S Barry